Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

The stock of U.S. pharmaceutical giant Eli Lilly (LLY) is up 3% on news that rival Pfizer (PFE) has ended development of its experimental ...

Eli Lilly (LLY) ended the recent trading session at $757.18, demonstrating a +0.38% swing from the preceding day's closing price. The stock's performance ... Estimates forecast earnings of $ ...

Eli Lilly (NYSE ... Typically, analysts assess and rate each stock once per quarter. Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide ...

Goldman Sachs forecasts Eli Lilly's AOM franchise revenue for the 2026-28 period to exceed consensus estimates by 10.3% to 8.9%. Secondly, the company's strategic approach to replicate the success ...

Most U.S. stocks rose, but the worst drop for UnitedHealth Group in a quarter century kept Wall Street in check.

Vandana Singh Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies Even as Donald Trump paused the reciprocal tariffs ...

S&P 500 futures rise as Wall Street reacts to mixed earnings and Fed comments. While Dow futures fall 583 points dragged by ...

Eli Lilly has emerged as a popular growth stock thanks to its strength in the ... Eisai actually revised its full-year 2024 forecast for Leqembi to 42.5 billion yen -- down from the initial ...